Evidence map›Paper›PMID 41639084›Full record

ArticleNPJ biofilms and microbiomes2026

Prucalopride, a serotonin type 4 receptor agonist, induces fast anxiolytic/antidepressant effects and concomitant changes in the gut microbiota.

Sofia Cussotto, Salma R Abdennebi, Isabelle Etting, Christine A Denny, René Hen, Romain Colle, Emmanuelle Corruble, Jean-Claude Alvarez, Denis J David, Indira Mendez-David

Abstract read
In one paragraph

Article in NPJ biofilms and microbiomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sofia CussottoUniversité Paris-Saclay, UVSQ, Centre de recherche en Epidémiologie et Santé des Populations (CESP), UMR 1018, CESP-Inserm, Team Moods, Faculté de Pharmacie, Bâtiment Henri Moissan, Orsay, France.
Salma R AbdennebiUniversité Paris-Saclay, UVSQ, Centre de recherche en Epidémiologie et Santé des Populations (CESP), UMR 1018, CESP-Inserm, Team Moods, Faculté de Pharmacie, Bâtiment Henri Moissan, Orsay, France.
Isabelle EttingDepartment of Pharmacology and Toxicology, Raymond Poincaré Hospital, GHU AP-HP, UVSQ/Paris-Saclay, Garches, France.
Christine A DennyDepartment of Psychiatry, Columbia University Irving Medical Center, New York; Division of Systems Neuroscience, New York State Psychiatric Institute, New York, NY, USA.
René HenDepartment of Psychiatry, Columbia University Irving Medical Center, New York; Division of Systems Neuroscience, New York State Psychiatric Institute, New York, NY, USA.
Romain ColleUniversité Paris-Saclay, Centre de recherche en Epidémiologie et Santé des Populations (CESP), MOODS UMR1018, CESP-Inserm, Team Moods, Faculté de Médecine, Le Kremin-Bicêtre, France.
Emmanuelle CorrubleUniversité Paris-Saclay, Centre de recherche en Epidémiologie et Santé des Populations (CESP), MOODS UMR1018, CESP-Inserm, Team Moods, Faculté de Médecine, Le Kremin-Bicêtre, France.
Jean-Claude AlvarezDepartment of Pharmacology and Toxicology, Raymond Poincaré Hospital, GHU AP-HP, UVSQ/Paris-Saclay, Garches, France.
Denis J DavidUniversité Paris-Saclay, UVSQ, Centre de recherche en Epidémiologie et Santé des Populations (CESP), UMR 1018, CESP-Inserm, Team Moods, Faculté de Pharmacie, Bâtiment Henri Moissan, Orsay, France. denis.david@universite-paris-saclay.fr.
Indira Mendez-DavidUniversité Paris-Saclay, UVSQ, Centre de recherche en Epidémiologie et Santé des Populations (CESP), UMR 1018, CESP-Inserm, Team Moods, Faculté de Pharmacie, Bâtiment Henri Moissan, Orsay, France.

Funding

Agence Nationale de la Recherche France 2030 program "ANR-11-IDEX-0003," from the Head Core call from Health and Drug Sciences Graduate school of the Université Paris-Saclay.Agence Nationale de la Recherche France 2030 program "ANR-11-IDEX-0003," from the OI HEALTHI of the Université Paris-SaclayBrain & Behavior Research Foundation 2017 and 2022 Young Investigator AwardColumbia University 2021 Schaefer Award Scholarship
6 · The paper itself

Abstract

Major Depressive Disorder (MDD) affects around 20% of people globally and is often comorbid with anxiety. This study investigates prucalopride, a serotonin type 4 receptor (5-HT

Indexed as

Anti-Anxiety AgentsAntidepressive AgentsBenzofuransGastrointestinal MicrobiomeSerotonin 5-HT4 Receptor AgonistsAnimalsAnxietyBehavior, AnimalCorticosteroneDisease Models, AnimalFluoxetineMaleMiceAnti-Anxiety AgentsAntidepressive AgentsBenzofuransCorticosteroneFluoxetineprucaloprideSerotonin 5-HT4 Receptor Agonists

Identifiers

PMID41639084
PMCPMC12979823

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.